➤预测期内,GLP-1 市场预计将以 11.1% 的复合年增长率增长;至 2035 年,生物制剂板块有望占据市场超 65% 份额。 参考文献 [1]ResearchAndMarkets.com. (2025, March 18). GLP-1 Market Industry Trends and Global Forecasts ...
After 12 months of GLP-1 agonist therapy, weight significantly decreased from 97.6 kg (95% CI: 92.7–102.5) to 90.0 kg (95% CI: 84.9–95.1) (p < 0.001). A1C levels also improved significantly, from 8.2% (95% CI: 7.9–8.6) to 7.6% (95% CI: 7.2–7.9) (p < 0.001). Basal ...
JAMA:That’s very interesting. I also wanted to talk about a newer agent, pemvidutide. This is a GLP-1 and glucagon dual receptor agonist, meaning it targets 2 hormones. A study of this drug that’s in developme...
Guidance for using compounding pharmacies to purchase GLP-1 agonists [47:15]; Data on retatrutide—a promising new triple receptor agonist in the pipeline [50:15]; Can GLP-1 agonists be beneficial for sleep apnea and immune function? [57:00]; Potential neuroprotective benefits of GLP-1 agon...
MDR-001 is a novel, orally bioavailable small-molecule GLP-1R agonist discovered using MindRank’s proprietary AI platform, Molecule Pro™. In the comprehensive preclinical studies, MDR-001 has demonstrated excellent functional potency and selectivity, with favorable ADME properties and oral ...
Semaglutide was the highest newly prescribed GLP-1 receptor agonist in 2023. The proportion of new users without FDA-approved indications rose from 0.21% to 0.37% from 2019 to 2023. New prescriptions of GLP-1 receptor agonists for the treatment of obesity have increased significantly among individu...
1. GlobalData Healthcare. Key opinion leaders on GLP-1 receptor agonist clinical trial design. Clinical Trials Arena. April 26, 2024. https://www.clinicaltrialsarena.com/analyst-comment/kols-glp-1-receptor-agonist-clinical-trial-design/ 2. WHO issues warning on falsified medicines used for diabe...
Additionally, our analysis could not discern the specific clinical indications for GLP-1RAs initiation during AKD due to the nature of database research, limiting our ability to fully contextualize prescribing decisions. Finally, the lack of detailed reasons for redialysis or mortality also constrains...
21 / GLP-1 Dual Receptor Agonist, a Therapeutic With Major Commercial Potential in Multiple Indications. Retrieved Nov 12, 2024, fromhttps://www.apollotx.com/news/apollo-therapeutics-signs-exclusive-ex-china-license-from-sunshin...
The invention relates to compounds having agonist activity at the GLP-1 (glucagon-like-peptide 1) and GLP-2 (glucagon-like peptide 2) receptors. The compounds find use, inter alia, in the prophylaxis or treatment of intestinal damage and dysfunction, regulation of body weight, and prophylaxis ...